Clinical Trial Update: Epigenetic Reprogramming in Relapse AML [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating epigenetic reprogramming for relapse acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Epigenetic Reprogramming Agent (Phase 1 trial)

Snippet

Sponsor: Michael Burke | Conditions: Leukemia, Acute Myeloid | Phase 1 | Status: TERMINATED